JP2013544842A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544842A5
JP2013544842A5 JP2013542143A JP2013542143A JP2013544842A5 JP 2013544842 A5 JP2013544842 A5 JP 2013544842A5 JP 2013542143 A JP2013542143 A JP 2013542143A JP 2013542143 A JP2013542143 A JP 2013542143A JP 2013544842 A5 JP2013544842 A5 JP 2013544842A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
alkyl
alkenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013542143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544842A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/062691 external-priority patent/WO2012075174A2/en
Publication of JP2013544842A publication Critical patent/JP2013544842A/ja
Publication of JP2013544842A5 publication Critical patent/JP2013544842A5/ja
Pending legal-status Critical Current

Links

JP2013542143A 2010-12-02 2011-11-30 皮膚修復のための化合物および方法 Pending JP2013544842A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41911510P 2010-12-02 2010-12-02
US61/419,115 2010-12-02
PCT/US2011/062691 WO2012075174A2 (en) 2010-12-02 2011-11-30 Compounds and methods for skin repair

Publications (2)

Publication Number Publication Date
JP2013544842A JP2013544842A (ja) 2013-12-19
JP2013544842A5 true JP2013544842A5 (enExample) 2015-01-29

Family

ID=45316123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013542143A Pending JP2013544842A (ja) 2010-12-02 2011-11-30 皮膚修復のための化合物および方法

Country Status (16)

Country Link
US (1) US20120142684A1 (enExample)
EP (2) EP3195863A1 (enExample)
JP (1) JP2013544842A (enExample)
KR (1) KR20130119958A (enExample)
CN (1) CN103282033A (enExample)
AR (1) AR084144A1 (enExample)
AU (1) AU2011336582A1 (enExample)
BR (1) BR112013015781A2 (enExample)
CA (1) CA2819471A1 (enExample)
CL (1) CL2013001579A1 (enExample)
MX (1) MX2013006163A (enExample)
RU (1) RU2013129262A (enExample)
SG (1) SG190947A1 (enExample)
TW (1) TW201307313A (enExample)
WO (1) WO2012075174A2 (enExample)
ZA (1) ZA201303949B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013001866A (es) * 2010-08-17 2013-05-22 Allergan Inc Agonistas de receptor de prostaglandina suptipo-2(ep2) o receptor de prostaglandina suptipo-4(ep4) para tratar la opacidad de la cornea
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
JP2015537028A (ja) * 2012-11-16 2015-12-24 アラーガン、インコーポレイテッドAllergan,Incorporated 皮膚修復のための組成物および方法
ES2730895T3 (es) * 2013-09-27 2019-11-13 Allergan Inc Compuestos y métodos para reparación cutánea

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000015608A1 (fr) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. Derives e de phenyl-prostaglandine a substitution-φ et medicaments les contenant comme ingredient actif
AU2002328338C1 (en) * 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
KR100826866B1 (ko) * 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ep4 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2004032965A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
MXPA05007341A (es) * 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2006137472A1 (ja) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. プロスタグランジン誘導体
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
BRPI0720254A2 (pt) * 2006-12-15 2014-01-07 Glaxo Group Ltd Derivados de benzamida como agonistas do receptor ep4
US20100081631A1 (en) * 2006-12-18 2010-04-01 Guang Liang Jiang Methods and compositions for treating gastrointenstial disorders
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092862A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092861A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
US20110111031A1 (en) * 2009-04-20 2011-05-12 Guang-Liang Jiang Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
MX2013001227A (es) * 2010-07-30 2013-04-24 Allergan Inc Compuestos y metodos para reparacion de piel.
WO2012024072A1 (en) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition

Similar Documents

Publication Publication Date Title
JP2013544842A5 (enExample)
JP2013536183A5 (enExample)
RU2013129262A (ru) Соединения и способы для восстановления кожи
RU2014113663A (ru) Композиции кожного наполнителя для лечения мелких морщин
JP2013517263A5 (enExample)
KR102292206B1 (ko) 티로신 유도체 및 이를 포함하는 조성물
JP2017214429A5 (enExample)
KR20100098633A (ko) 자색반병의 치료를 위한 조성물 및 방법
US20120136011A1 (en) Compounds and methods for skin repair
JP2017533972A5 (enExample)
JP2018520198A5 (enExample)
JP2016514150A5 (enExample)
RU2014128387A (ru) Ингибиторы рi3к для лечения фиброзных заболеваний
DK2004235T3 (da) Sammensætning til kosmetisk eller farmaceutisk-dermatologisk anvendelse
RU2014150946A (ru) Способ снижения веса
RU2014152196A (ru) Способ улучшения функции печени
JP2014517038A5 (enExample)
JP5734953B2 (ja) やけどによる損傷の治療または予防用薬学的組成物
JP2018534358A (ja) Vegf阻害剤の局所投与による皮膚障害の処置
EA201890714A1 (ru) Композиция для лечения бесплодия у субъекта женского пола
JP2017528517A (ja) 多汗症を治療するための方法
TW201632191A (zh) 一種用於促進傷口癒合或預防、減少傷口疤痕生成的醫藥組合物
JP2016531872A5 (enExample)
US20230372583A1 (en) Compositions and methods for treating facial volume defects
BR112024001969A2 (pt) Composição farmacêutica líquida de clemizol, método de preparação da composição farmacêutica líquida e uso de um composto clemizol